Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

Both of these points are likely to be of relevance to the management of patients with AF. Patients with heart failure, irrespective of ejection fraction, frequently have AF. Disentangling whether a ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

Older adults with HF with preserved ejection fraction and low vs. high life-space mobility had double the risk for all-cause ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Human Heat Tolerance Lower Than Previously Believed: Study FindsA study from the University of Ottawa’s Human and ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...